Thalomid, Thalidomide Celgene, Thalidomide Pharmion (thalidomide) is a small molecule pharmaceutical. Thalidomide was first approved as Thalomid on 1998-07-16. It is used to treat aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, and erythema multiforme amongst others in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon. Thalomid's patent is valid until 2023-12-09 (FDA).
|Trade Name||Thalidomide Celgene, Thalidomide Pharmion|
|Indication||aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, erythema multiforme, erythema nodosum, graft vs host disease, langerhans-cell histiocytosis, leprosy, multiple myeloma, renal cell carcinoma, rheumatoid arthritis, waldenstrom macroglobulinemia|
|Drug Class||Thalidomide derivatives|